Lenalidomide and pomalidomide based triplet combination regimens for myeloma patients receives approval from the European Commission
The European Commission has approved two of Celgene’s IMiD ® -based combination regimens: Lenalidomide (Revlimid®) in combination with bortezomib and dexamethasone (RVd) in adult patients with previously untreated multiple myeloma who are not eligible for transplant Pomalidomide (Imnovid®) in combination with bortezomib and dexamethasone (PVd), in adult patients with multiple myeloma, who have received at…